Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

MIM Software Showcases a Single Platform Viewing Solution for PET, CT, MRI, and Nuclear Medicine Exams at SNMMI 2013

MIM Software Inc., a leading global provider of medical imaging software, announced they will be showcasing a new version of MIM Encore that provides a single platform for viewing PET, CT, MRI and Nuclear Medicine exams at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2013 Annual Meeting.

June 11, 2013

SNMMI 2013 Image of the Year: Radium-223 Dichloride Response in Bone Metastases in Breast Cancer Patients

An 18F-FDG positron emission tomography/computed tomography (PET/CT) scan illustrating the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease has been selected as the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2013 Image of the Year. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNMMI’s 2013 Annual Meeting in Vancouver, British Columbia, Canada.

June 11, 2013

Sequester bites NIH funding, Alzheimer’s research

With increasing prevalence of Alzheimer’s disease threatening to bankrupt Medicare and Medicaid by 2050, the fiscal pinch of the sequester could extend decades into the future and compromise already-limited progress on Alzheimer’s disease prevention and treatment. A letter in the New York Times detailed the data.

June 10, 2013

Siemens Introduces Continuous FlowMotion PET•CT

At the 2013 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 8-12 in Vancouver, B.C., Canada, Siemens Healthcare (booth 720) will introduce Biograph mCT Flow – a groundbreaking new positron emission tomography/computed tomography (PET/CT) system that, for the first time ever, overcomes the limitations of conventional bed-based PET/CT with FlowMotion, a revolutionary new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

June 7, 2013

IBA Molecular, MIM Software Sign Agreement for PETLinQ Enhancement

IBA Molecular North America, Inc. (IBA Molecular) and MIM Software Inc. (MIM Software™) have announced an agreement to co-develop enhancements to the IBA Molecular PETLinQ™ suite of products

June 7, 2013

Siemens’ PETNET Solutions and Lilly Sign Amyvid EU Manufacturing Agreement

PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., will soon begin manufacturing Eli Lilly and Company’s AmyvidTM (Florbetapir (18F)) radiopharmaceutical in the United Kingdom, as well as in Spain and France, after signing a manufacturing services agreement with Eli Lilly and Company. Siemens’ PETNET Solutions will function as a contract manufacturer for Lilly after Lilly’s diagnostic radiopharmaceutical received marketing authorisation from the European Commission in early 2013.

June 4, 2013

Radiation Therapy leaders gather for ProteusONE demonstration

IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that today 60 radiation therapy leaders travelled to Belgium to discover the first Proteus®ONE in factory.

June 3, 2013

Patients and Technologists Benefit from Reduced Dose of UltraSPECT Image Reconstruction Software

UltraSPECT, a leading provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces today the installation of its proprietary Wide Beam Reconstruction (WBR™) software at nearly ten healthcare facilities.

May 30, 2013